

## For Health Professionals Who Care for People with Cancer

### Inside This Issue:

#### Editor's Choice

##### New Programs

- **GUBGRT** Gemcitabine and Radiation Therapy for Treatment of Muscle-Invasive Urothelial Cancer
- **GUBMITCART** Mitomycin, Capecitabine and Radiation Therapy for Treatment of Muscle-Invasive Bladder Cancer
- **GUBMITFURT** Mitomycin, Fluorouracil and Radiation Therapy for Treatment of Muscle-Invasive Bladder Cancer
- **ULKBLINF** Blinatumomab with Consolidation Chemotherapy for Treatment of Ph-Negative Pre-B-Cell ALL
- **LYAVDNIV** Doxorubicin, Vinblastine, Dacarbazine and Nivolumab for Treatment of Hodgkin Lymphoma

##### Expansion of Existing Programs

- **GUBPWRT** Weekly Cisplatin and Concurrent Radiation for Treatment of Locally Advanced Bladder Cancer
- **LYVENOB** Venetoclax and Obinutuzumab for Treatment of Previously-Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

#### Practice Standards and Policies

Dose Banding: ipilimumab, nivolumab  
Transitioning from Reference Biologics to Biosimilars  
Provincial Systemic Therapy Policy Documents

#### Cancer Drug Manual®

**Revised** palbociclib, vinblastine, vincristine, vinorelbine

#### Benefit Drug List

**New** GUBGRT, GUBMITCART, GUBMITFURT, ULKBLINF, LYAVDNIV, blinatumomab (pediatric), nivolumab (pediatric)

**Revised** pediatric: blinatumomab

**Deleted** GIGECC

#### Protocols, PPPOs and Patient Handouts

**New** **GU** GUBGRT, GUBMITCART, GUBMITFURT **LK** ULKBLINF **LY** LYAVDNIV **SM** SMNAIPNI

**Revised** **GI** GIAJNIV, GIATZB, GIAVCAP, GIAVCAPB, GICAPIRI, GICAPOX, GIGAVCOXN, GIGAVFFOXN, GIPAVFFIRI, GIPAVFFOX **GO** GOOVBEVG **GU** UGUAJNIV, UGUAJNIV4, GUAVIPNI, GUAVNIV, GUAVNIV4, GUAVNIVC, GUAVNIVC4, GUBPWRT, GUPADT **HN** HNAVNIV, HNAVNIV4 **LK** ULKAMLAVEN, ULKBLIN, ULKMRDBLIN **LU** LUAJNIVPC, LUAJNIVPP, LUAVNIV, LUAVNIV4, LUAVPCIPNI, LUAVPPIPNI, LUMMIPNI, LUMMIPNI3 **LY** LYEPOCHR, LYNIV, LYNIV4, LYVENOB **MY** UMYPOMDEX **SA** SATEMBEV **SM** SMAJNIV, SMAJNIV4, SMAVALIPNI, SMAVFIPI, SMAVIPI, SMAVIPNI, SMAVNIV, SMAVNIV4, SMNAIPNI

#### Resources and Contact Information

### Editor's Choice

#### New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 December 2025. Full details of all treatment programs are available in the [Chemotherapy Protocols](#) section of the BC Cancer website.

#### Genitourinary

**Gemcitabine and Radiation Therapy for Treatment of Muscle-Invasive Urothelial Cancer (GUBGRT)** – The BC Cancer Genitourinary Tumour Group is implementing weekly gemcitabine as a radiosensitizer during radiation therapy for patients with muscle-invasive urothelial cancer (MIBC). Cisplatin is often used concurrently with radiation, but cisplatin is not appropriate in all patients. Gemcitabine can serve as an alternative for patients who are ineligible for cisplatin, including patients with renal insufficiency or pre-

## Editor's Choice

existing hearing loss. Gemcitabine has previously been shown to be effective as a radiosensitizer in MIBC in terms of complete response rate and rate of freedom from distant metastasis.<sup>1,2</sup>

**Mitomycin, Fluoropyrimidine and Radiation Therapy for Treatment of Muscle-Invasive Bladder Cancer (GUBMITCART, GUBMITFURT)** – The BC Cancer Genitourinary Tumour Group is also implementing combined modality treatment with mitomycin, fluoropyrimidine and radiation therapy for patients with MIBC. Concurrent chemoradiotherapy using mitomycin with either fluorouracil or capecitabine has demonstrated high response rates and improved locoregional control in patients with MIBC.<sup>3,4</sup>

### Leukemia

**Blinatumomab with Consolidation Chemotherapy for Treatment of Philadelphia Chromosome (Ph)-Negative Pre-B-Cell Acute Lymphoblastic Leukemia (ULKBLINF)** – The BC Cancer Leukemia/BMT Tumour Group is implementing blinatumomab in the treatment of patients with newly-diagnosed Philadelphia chromosome(Ph)-negative CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). Patients with documented complete remission following initial induction chemotherapy will proceed to front-line consolidation therapy that includes blinatumomab. Incorporating blinatumomab into standard front-line multiphase consolidation chemotherapy is expected to increase the chance of cure and reduce the risk of relapse in patients with newly-diagnosed disease. Treatment is delivered at Vancouver General Hospital and requires BC Cancer Compassionate Access Program (CAP) approval.

The randomized, active-controlled phase III ECOG1910 trial investigated the addition of blinatumomab to front-line multiphase consolidation chemotherapy in patients with Ph-negative, CD19-positive B-cell ALL in remission after induction chemotherapy.<sup>5,6</sup> Blinatumomab plus consolidation chemotherapy, compared with consolidation chemotherapy alone, was associated with clinically meaningful improvements in overall survival and relapse-free survival, irrespective of minimal residual disease (MRD) status. A higher incidence of neuropsychiatric adverse events was reported in the blinatumomab group than in the chemotherapy-only group. Other adverse events were similar between the two groups.

### Lymphoma

**Doxorubicin, Vinblastine, Dacarbazine and Nivolumab for Hodgkin Lymphoma (LYAVDNIV)** – The BC Cancer Lymphoma Tumour Group is introducing nivolumab in combination with doxorubicin, vinblastine and dacarbazine (N-AVD) as the new preferred standard of care in newly-diagnosed advanced stage classic Hodgkin lymphoma (cHL). Dosing of AVD (on days 1 and 15 of each cycle) is the same as the dosing used with existing AVD-based regimens (LYABVD, LYAVDBV). Nivolumab is administered at 3 mg/kg to a maximum of 240 mg on days 1 and 15 of each cycle. Treatment is continued for up to 6 cycles. Primary prophylaxis with filgrastim is not mandatory with N-AVD but may be considered in patients over 60 years of age.

The randomized, controlled phase III SWOG1826 trial compared the efficacy and safety of N-AVD with that of brentuximab-AVD (BV-AVD) in patients with newly-diagnosed stage III or IV cHL.<sup>7,8</sup> Nivolumab-AVD was associated with a clinically important improvement in progression-free survival and event-free survival compared to BV-AVD. Overall, N-AVD had a more favourable adverse event profile. Although neutropenia was observed in more patients in the N-AVD group, this was consistent with the required use of filgrastim as primary prophylaxis for patients in the BV-AVD group, and the rates of febrile neutropenia, sepsis and infections were similar between groups. A substantially higher incidence of peripheral neuropathy was seen with BV-AVD.

## Editor's Choice

### References:

1. Choudhury A, Swindell R, Logue JP, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. *J Clin Oncol* 2011;29(6):733-738. <https://doi.org/10.1200/JCO.2010.31.5721>
2. Coen JJ, Zhang P, Saylor PJ, et al. Bladder preservation with twice-a-day radiation plus fluorouracil/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG/RTOG 0712 – a randomized phase II trial. *J Clin Oncol* 2019;37(1):44-51. <https://doi.org/10.1200/JCO.18.00537>
3. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. *New Engl J Med* 2012;366(16):1477-1488. <https://doi.org/10.1056/NEJMoa1106106>
4. Voskuilen CS, van de Kamp MW, Schuring N, et al. Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: a convenient alternative to 5-fluorouracil. *Radiother Oncol* 2020;150:275-280. <https://doi.org/10.1016/j.radonc.2020.07.057>
5. Canada's Drug Agency CDA-AMC. Reimbursement Recommendation. Blinatumomab (Blinicyto®). *Canadian Journal of Health Technologies* 2025;5(5):1-42. <https://doi.org/10.51731/cjht.2025.1127>
6. Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. *N Engl J Med* 2024;391(4):320-333. <https://doi.org/10.1056/NEJMoa2312948>
7. Canada's Drug Agency CDA-AMC. Reimbursement Recommendation. Nivolumab. *Canadian Journal of Health Technologies* 2025;5(8):1-11. <https://doi.org/10.51731/cjht.2025.1190>
8. Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma. *N Engl J Med* 2024;391(15):1379-1389. <https://doi.org/10.1056/NEJMoa2405888>

## Expansion of Existing Programs

### Genitourinary

**Weekly Cisplatin and Concurrent Radiation for Treatment of Locally Advanced Bladder Cancer (GUBPWRT)** – The BC Cancer Genitourinary Tumour Group is expanding the eligibility criteria to include stages T2 to T4 bladder cancer. This treatment protocol is intended both for patients receiving radical (curative intent) radiotherapy for locally advanced MIBC, and for patients receiving radiotherapy for improved local control in the high-grade palliative setting.

### Lymphoma

**Venetoclax and Obinutuzumab for Treatment of Previously-Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (LYVENOB)** – The BC Cancer Lymphoma Tumour Group is expanding the eligibility criteria for venetoclax-obinutuzumab (VO) to include patients who are also otherwise eligible for fludarabine-cyclophosphamide-rituximab (FCR). This includes younger, fit patients with good risk disease and a low burden of coexisting conditions. The randomized, open-label, phase III GAIA-CLL13 trial demonstrated a significant improvement in progression-free survival of VO over FCR, including among younger fit patients.<sup>1,2</sup> Venetoclax-obinutuzumab is associated with reduced toxicity compared to FCR, including reduced incidence of febrile neutropenia, infections, and risk of secondary myeloid malignancies. Patients who recently started other first-line treatment between 01 June 2025 and 01 December 2025 may switch to LYVENOB.

### References:

1. Eichhorst B, Niemann CU, Kater AP, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. *N Engl J Med* 2023;388(19):1739-1754. <https://doi.org/10.1056/NEJMoa2213093>
2. Canada's Drug Agency CDA-AMC. Reimbursement Recommendation. Venetoclax (Venclexta®). *Canadian Journal of Health Technologies* 2024;4(12):1-27. <https://doi.org/10.51731/cjht.2024.1046>

## Practice Standards and Policies

All Systemic Therapy policies are on the BC Cancer section of [Shared Health Organizations Portal \(SHOP\)](#).

### Dose Banding: Ipilimumab, Nivolumab

As part of the continued dose banding rollout at BC Cancer:

- standardized dose bands for **ipilimumab** and **nivolumab** have been integrated into all protocols, provincial preprinted orders (PPPOs) and the Cerner system
- Systemic Therapy [Procedure III-140: Management of Dose Banded Cancer Drug Treatments](#) continues to be updated to reflect the drugs approved for dose banding

### Transitioning from Reference Biologics to Biosimilars

Long-term clinical evidence supports comparability between the reference biologics **trastuzumab** (HERCEPTIN) and **bevacizumab** (AVASTIN) and their biosimilars.

As of 01 December 2025:

- All remaining patients being treated with one of these two reference biologics are to be transitioned to a biosimilar.
- Access to HERCEPTIN and AVASTIN requires BC Cancer Compassionate Access Program (CAP) approval. Approval will only be granted for safety or significant adverse event reasons.
- CON sites will have a 6-month transition period to use up old inventory of the reference biologics. New inventory will not be reimbursed past the transition date without BC Cancer approval.

In the future, as BC Cancer funds new biosimilars, patients on reference biologics will be transitioned to the biosimilar and access to the reference biologic will require CAP approval. This has been reflected in the updated Systemic Therapy [Policy III-190: Oncology Biosimilars Utilization](#).

There are no changes to BC Cancer Cerner PowerPlans or PPPOs.

Questions can be sent to [ProvincialSystemicOffice@bccancer.bc.ca](mailto:ProvincialSystemicOffice@bccancer.bc.ca).

### Provincial Systemic Therapy Policy Documents

BC Cancer Provincial Systemic Therapy has developed an [Ethical Framework to Guide Decision-Making in Systemic Therapy](#). This equity-informed multi-value ethical framework will guide allocation decisions when demand for healthcare services exceeds available resources. The above link is accessible to those with PHSA email addresses; for those outside of PHSA wanting to review, please email Provincial Systemic Therapy at [provincialsystemicoffice@bccancer.bc.ca](mailto:provincialsystemicoffice@bccancer.bc.ca).

Provincial Systemic Therapy has also developed two prioritization guidelines to guide decision-making when demand for systemic therapy services exceeds available resources.

- [Prioritization Guidelines for Cancer Drug Treatment Implementation](#)
- [Systemic Therapy Prioritization Guidelines for Individual Patients](#)

## Provincial Systemic Therapy Policy Documents

New versions of the following policy documents are available. Revisions to the documents were minimal and the result of the three-year review cycle for policy documents.

- [III-100: Laboratory Tests – Ordering by Pharmacists](#)
- [III-150: Medication Brand Change Requests](#)
- [III-160: Selecting Patient Medication Handouts](#)

## Cancer Drug Manual<sup>®</sup>

All documents are available in the [Cancer Drug Manual<sup>®</sup>](#) on the BC Cancer website.

## Revised CDM Documents

### Palbociclib Monograph

*Side Effects:* added venous thromboembolic events to *Side Effects* table and removed pulmonary embolism

*Interactions:* added simvastatin interaction to table

*Supply and Storage:* added new generic formulation, removed information pertaining to lactose content as capsules are no longer available, and updated packaging information

*Dosage Guidelines:* removed information distinguishing between capsules and tablets as capsules are no longer available

### Palbociclib Patient Handout:

*Header/Footer and Banner bar:* removed information pertaining to “tablets” because there is no need to distinguish between tablets and capsules

*Interaction bullet:* added simvastatin as an example of an interacting drug

*Emergent bullets:* added VTE to signs of blood clot

*Throughout:* updated template language

### Vinblastine Monograph

*Cautions:* updated *Fertility, Pregnancy, and Breastfeeding* sections

*Side Effects:* replaced tumour lysis paragraph with standardized Hyperuricemia paragraph

*Supply and Storage:* updated current brands

*Parenteral Administration:* updated Intermittent infusion

*Dosage Guidelines:* removed instructions regarding Appendix for managing myelosuppression

### Vincristine Monograph

*Cautions:* updated *Fertility* and *Pregnancy* sections

*Side Effects:* updated Hyperuricemia paragraph

*Parenteral Administration:* updated Intermittent infusion

*Dosage Guidelines:* removed instructions regarding Appendix for managing myelosuppression

### Vinorelbine Monograph

*Cautions:* updated *Fertility* and *Pregnancy* sections

*Side Effects:* updated Hyperuricemia paragraph

*Supply and Storage:* updated current brands

*Parenteral Administration:* updated Intermittent infusion

*Dosage Guidelines:* removed instructions regarding Appendix for managing myelosuppression

## Benefit Drug List

### New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 December 2025:

Protocol Title	Protocol Code	Benefit Status
Treatment of Muscle Invasive Urothelial Cancer using <b>Gemcitabine</b> and Radiation Therapy	<b>GUBGRT</b>	Class I
Combined Modality Treatment for Muscle Invasive Bladder Cancer using <b>Mitomycin, Capecitabine</b> and Radiation Therapy	<b>GUBMITCART</b>	Class I
Combined Modality Treatment for Muscle Invasive Bladder Cancer using <b>Mitomycin, Fluorouracil</b> and Radiation Therapy	<b>GUBMITFURT</b>	Class I
Treatment of Philadelphia Chromosome (Ph)-Negative Pre-B-Cell Acute Lymphoblastic Leukemia using <b>Blinatumomab</b> in Combination with Consolidation Chemotherapy	<b>ULKBLINF</b>	Restricted
Treatment of Hodgkin Lymphoma with <b>Doxorubicin, Vinblastine, Dacarbazine</b> and <b>Nivolumab</b>	<b>LYAVDNIV</b>	Class I
Treatment of pediatric patients with Philadelphia chromosome-negative, CD19-positive pre-B-cell acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy, who are in remission, regardless of minimal residual disease (MRD) status, using <b>blinatumomab</b>	<b>Pediatric</b>	Restricted
Treatment of pediatric patients (12 years and older) with bulky stage II, stage IIb and IV Hodgkin lymphoma using 6 cycles of <b>nivolumab</b> with <b>doxorubicin, vinblastine, and dacarbazine</b>	<b>Pediatric</b>	Class I

### Revised Programs

The following treatment programs have been revised on the BC Cancer [Benefit Drug List](#) effective 01 December 2025:

Protocol Title	Protocol Code	Benefit Status
Treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory pre-B-cell acute lymphoblastic leukemia using <b>blinatumomab</b> ✓ Previously approved for second or later relapse; now approved for first relapse	<b>Pediatric</b>	Restricted

### Deleted Programs

The following treatment program has been deleted on the BC Cancer [Benefit Drug List](#) effective 01 December 2025:

Protocol Title	Protocol Code	Benefit Status
Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Epirubicin, Cisplatin and Capecitabine	<b>GIGECC</b>	Class I

## Highlights of New & Revised Protocols, PPPOs and Patient Handouts

**BC Cancer Treatment Protocols, Provincial Preprinted Orders (PPPOs) and Patient Handouts** are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

### NEW Protocols, PPPOs and Patient Handouts (*new documents checked* ☒)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GUBGRT</b>	Treatment of Muscle Invasive Urothelial Cancer using Gemcitabine and Radiation Therapy	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<b>GUBMITCART</b>	Combined Modality Treatment for Muscle Invasive Bladder Cancer using Mitomycin, Capecitabine and Radiation Therapy	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<b>GUBMITFURT</b>	Combined Modality Treatment for Muscle Invasive Bladder Cancer using Mitomycin, Fluorouracil and Radiation Therapy	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<b>ULKBLINF</b>	Treatment of Philadelphia Chromosome (Ph)-Negative Pre-B-Cell Acute Lymphoblastic Leukemia using Blinatumomab in Combination with Consolidation Chemotherapy	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<b>LYAVDNIV</b>	Treatment of Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Nivolumab	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<b>SMNAIPNI</b>	Neoadjuvant Treatment of Stage III Melanoma using Ipilimumab and Nivolumab	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

### REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GI   Gastrointestinal</b>				
<b>GIAJNIV</b>	Adjuvant Treatment of Resected Esophageal or Gastroesophageal Junction Cancer using Nivolumab	<i>Dose banding added; hyperlinks updated</i>	<i>Dose banding added; Return Appointment Orders and pretreatment metrics clarified</i>	---
<b>GIATZB</b>	First-Line Treatment of Advanced Hepatocellular Carcinoma using Atezolizumab and Bevacizumab	---	---	<i>Serious and Other Side Effects tables updated</i>
<b>GIAVCAP</b>	Palliative Therapy of Advanced Gastrointestinal Cancer using Capecitabine	---	---	<i>Eligibility updated</i>
<b>GIAVCAPB</b>	Palliative Therapy of Metastatic Colorectal Cancer using Capecitabine and Bevacizumab	<i>Dose banding reformatted</i>	<i>Dose banding reformatted</i>	---



## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GICAPIRI</b>	Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Irinotecan and Capecitabine in Patients Unsuitable for GEOFIRI	---	---	<i>Eligibility updated</i>
<b>GICAPOX</b>	Palliative Combination Chemotherapy for Metastatic Colorectal or Biliary Tract Cancer using Oxaliplatin and Capecitabine	---	---	<i>Eligibility updated</i>
<b>GIGAVCOXN</b>	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Capecitabine and Nivolumab	<i>Dose banding added for nivolumab</i>	<i>Dose banding added for nivolumab</i>	---
<b>GIGAVFFOXN</b>	First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab	<i>Dose banding added; Cautions clarified; hyperlinks updated</i>	<i>Dose banding added; Treatment and Return Appointment Orders clarified</i>	---
<b>GIPAVFFIRI</b>	Treatment of Metastatic Pancreatic or Biliary Tract Cancer using Irinotecan, Fluorouracil and Leucovorin	---	---	<i>Eligibility updated</i>
<b>GIPAVFFOX</b>	Palliative Combination Chemotherapy for Metastatic Pancreatic or Biliary Tract Cancer using Oxaliplatin, Fluorouracil, and Leucovorin	---	---	<i>Eligibility updated</i>
<b>GO   Gynecologic Oncology</b>				
<b>GOOVBEVG</b>	Treatment of Platinum-Resistant or -Refractory Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine	<i>Exclusions and Treatment clarified; TALLman lettering and hyperlink added</i>	---	---
<b>GU   Genitourinary</b>				
<b>UGUAINIV</b>	Adjuvant Treatment of Resected Urothelial Carcinoma using Nivolumab	<i>Dose banding added; Tests and treatment duration clarified; hyperlinks updated</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>UGUAINIV4</b>	Adjuvant Treatment of Resected Urothelial Carcinoma using 4-Weekly Nivolumab	<i>Dose banding added; Tests and treatment duration clarified; hyperlinks updated</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>GUAVIPNI</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Ipilimumab and Nivolumab	<i>Dose banding and TALLman lettering added; Tests clarified</i>	<b>Induction and Maintenance PPPOs:</b> <i>Dose banding added; Tests clarified</i>	---
<b>GUAVNIV</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab	<i>Dose banding and TALLman lettering added; Tests clarified</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---



## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GUAVNIV4</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab	<i>Dose banding and TALLman lettering added; Tests clarified</i>	<i>Dose banding added; Tests clarified</i>	---
<b>GUAVNIVC</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using Nivolumab and Cabozantinib	<i>Dose banding added</i>	<i>Dose banding added; Treatment clarified</i>	---
<b>GUAVNIVC4</b>	Treatment of Metastatic or Advanced Renal Cell Carcinoma using 4-Weekly Nivolumab and Cabozantinib	<i>Dose banding added; treatment duration clarified</i>	<i>Dose banding added; Treatment and Tests clarified</i>	---
<b>GUBPWRT</b>	Treatment of Locally Advanced Bladder Cancer with Weekly Cisplatin and Concurrent Radiation	<i>Contact Physician, Eligibility, Treatment and References updated; Tests clarified; Antiemetics sections removed; Premedications section added</i>	<i>Prechemo metric timeframe updated; Tests clarified</i>	---
<b>GUPADT</b>	Androgen Deprivation Therapy for Prostate Cancer	<i>Baseline tests updated</i>	---	---
<b>HN   Head and Neck</b>				
<b>HNAVNIV</b>	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using Nivolumab	<i>Dose banding added; Tests clarified; Precautions updated</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>HNAVNIV4</b>	Palliative Therapy for Unresectable, Platinum-Refractory, Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck using 4-Weekly Nivolumab	<i>Dose banding added; Tests clarified; Premedications updated</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>LK   Leukemia</b>				
<b>ULKAMLAVEN</b>	Therapy of Acute Myeloid Leukemia using Azacitidine and Venetoclax	<i>Eligibility, Treatment, GCSF and antifungal guidance updated</i>	---	---
<b>ULKBLIN</b>	Treatment of Philadelphia Chromosome (Ph)-Positive or Ph-Negative Refractory or Relapsed Pre-B-Cell Acute Lymphoblastic Leukemia with Blinatumomab	<i>Tests updated</i>	---	---
<b>ULKMRDBLIN</b>	Treatment of Pre-B-Cell Acute Lymphoblastic Leukemia with Minimal Residual Disease using Blinatumomab	<i>Tests updated</i>	---	---
<b>LU   Lung</b>				
<b>LUAJNIVPC</b>	Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, Carboplatin and Paclitaxel	<i>Dose banding added; Eligibility and Dose Modifications clarified; duplicate hyperlink removed</i>	<i>Dose banding added; Tests clarified</i>	---

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>LUAJNIVPP</b>	Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum	<i>Dose banding added; Eligibility and Treatment clarified</i>	<i>Dose banding added; Tests, infusion durations and units clarified</i>	---
<b>LUAVNIV</b>	Treatment of Advanced Non-Small Cell Lung Cancer using Nivolumab	<i>Dose banding and hyperlink added; Eligibility and Tests clarified</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>LUAVNIV4</b>	Treatment of Advanced Non-Small Cell Lung Cancer using 4-Weekly Nivolumab	<i>Dose banding and hyperlink added; Eligibility clarified</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>LUAVPCIPNI</b>	First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer with Paclitaxel, Carboplatin, Ipilimumab and Nivolumab	<i>Dose banding added; Eligibility and Dose Modifications clarified</i>	<b>Cycle 1 &amp; 2 PPPO:</b> <i>Dose banding added; Treatment and Tests clarified</i> <b>Cycle 3+ PPPO:</b> <i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>LUAVPPIPNI</b>	First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer with Platinum, Pemetrexed, Ipilimumab and Nivolumab	<i>Dose banding added; Eligibility, Tests, infusion duration, units and Dose Modifications clarified; hyperlink added</i>	<b>Cycle 1 &amp; 2 PPPO:</b> <i>Dose banding added; Tests, units and infusion rates clarified</i> <b>Cycle 3+ PPPO:</b> <i>Dose banding added; Tests clarified</i>	
<b>LUMMIPNI</b>	Treatment of Malignant Mesothelioma using Ipilimumab and Nivolumab	<i>Dose banding added; Tests clarified; duplicate hyperlinks removed</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>LUMMIPNI3</b>	Treatment of Malignant Mesothelioma using Ipilimumab and 3-Weekly Nivolumab	<i>Dose banding added; Tests clarified; duplicate hyperlinks removed</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>LY   Lymphoma</b>				
<b>LYEPOCHR</b>	Treatment of Lymphoma with Dose-Adjusted Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone and Rituximab with Intrathecal Methotrexate	---	<b>Outpatient PPPO:</b> <i>IT shorthand removed; infusion rates added; Treatment section reformatted</i>	---

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
LYNIV	Treatment of Relapsed or Refractory Hodgkin Lymphoma using Nivolumab	<i>Dose banding added; Precautions and hyperlinks updated</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
LYNIV4	Treatment of Relapsed or Refractory Hodgkin Lymphoma using 4-Weekly Nivolumab	<i>Dose banding and hyperlink added; Precautions updated</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
LYVENOB	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma using Venetoclax and Obinutuzumab	<i>Eligibility and References updated</i>	---	---
<b>MY   Myeloma</b>				
UMYPOMDEX	Therapy of Multiple Myeloma using Pomalidomide with Dexamethasone	---	<i>Tests and steroid administration clarified; height, weight and BSA removed</i>	---
<b>SA   Sarcoma</b>				
SATEMBEV	Therapy for Advanced Solitary Fibrous Tumours and Hemangiopericytoma using Temozolomide and Bevacizumab	<i>Dose banding reformatted</i>	---	---
<b>SM   Skin and Melanoma</b>				
SMAJNIV	Adjuvant Treatment of Resected Melanoma using Nivolumab	<i>Dose banding and hyperlink added; Tests clarified</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
SMAJNIV4	Adjuvant Treatment of Resected Melanoma using 4-Weekly Nivolumab	<i>Dose banding and hyperlink added; Tests clarified</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
SMAVALIPNI	Treatment of Unresectable or Metastatic Melanoma using Alternative Dosing Regimen of Ipilimumab and Nivolumab	<i>Dose banding and hyperlink added; Tests clarified</i>	<b>Induction and Maintenance PPPOs:</b> <i>Dose banding added; Tests clarified</i>	---
SMAVFIPI	First-Line Treatment of Unresectable or Metastatic Melanoma using Ipilimumab	<i>Dose banding and hyperlink added; Tests clarified; Precautions updated</i>	<i>Dose banding added; height removed; Tests clarified</i>	---
SMAVIPI	Treatment of Unresectable or Metastatic Melanoma using Ipilimumab	<i>Dose banding and hyperlink added; Tests clarified; Precautions updated</i>	<i>Dose banding added; height removed; Tests clarified</i>	---

## REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>SMAVIPNI</b>	Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab	<i>Dose banding and hyperlink added; Tests clarified</i>	<b>Induction and Maintenance PPPOs:</b> <i>Dose banding added; Treatment and Tests clarified</i>	---
<b>SMAVNIV</b>	Treatment of Unresectable or Metastatic Melanoma using Nivolumab	<i>Dose banding and hyperlink added; Precautions updated</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>SMAVNIV4</b>	Treatment of Unresectable or Metastatic Melanoma using 4-Weekly Nivolumab	<i>Dose banding and hyperlink added; Precautions updated</i>	<i>Dose banding added; height and BSA removed; Tests clarified</i>	---
<b>SMNAIPNI</b>	Neoadjuvant Treatment of Stage III Melanoma using Ipilimumab and Nivolumab	<i>Dose banding added; Tests and Treatment clarified</i>	<i>Dose banding added; Tests clarified</i>	---

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 <a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCCancerPPNAdmin@phsa.ca">BCCancerPPNAdmin@phsa.ca</a>
Provincial Systemic Therapy Network	604-877-6000 x 672247	<a href="mailto:ProvincialSystemicOffice@bccancer.bc.ca">ProvincialSystemicOffice@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)  
 Jelena Mucovic, BScPharm (Assistant Editor)  
 Mario de Lemos, PharmD, MSc(Oncol)  
 Jeevan Dosanjh, RN, BScN, MN

Alina Gerrie, MD, MPH, FRCPC  
 Alison Pow, BScPharm  
 Yuna Jang, RN